Salmeterol xinafoate

Bezeichnung:Salmeterol xinafoate

CAS-Nr94749-08-3

Englisch Name:Salmeterol xinafoate

CBNumberCB2751968

SummenformelC36H45NO7

Molgewicht603.74

MOL-Datei94749-08-3.mol

Salmeterol xinafoate physikalisch-chemischer Eigenschaften

Schmelzpunkt	137-138°C
storage temp.	2-8°C
Löslichkeit	H₂O: slightly soluble
Aggregatzustand	solid
Farbe	white
Merck	14,8337
InChIKey	XTZNCVSCVHTPAI-UHFFFAOYSA-N
CAS Datenbank	94749-08-3(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xi
R-Sätze:	36/37/38
S-Sätze:	22-24/25-36-26
WGK Germany	3
RTECS-Nr.	QJ1970500
HS Code	2922504500

Gefahreninformationscode (GHS)

Salmeterol xinafoate Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
Beschreibung
Salmeterol hydroxynaphthoate is a new long-acting β2-selective adrenoceptor agonist introduced as a bronchodilator for the treatment of reversible airway obstruction in asthma and chronic bronchitis. It has bronchodilatory activity as intense and four times longerlasting than equivalent doses of salbutamol. Salmeterol hydroxynaphthoate is reported to be the first bronchodilator with significant anti-inflammatory activity and hence could complement prophylactic corticosteroid therapy.
Beschreibung
Salmeterol is a long-acting β₂-adrenergic receptor agonist (β₂-AR; EC₅₀s = 0.79, 63.1, and 9.4 nM for β₂-, β₁-, and β₃-ARs, respectively). It inhibits electrically-stimulated contraction of isolated guinea pig trachea strips (EC₅₀ = 2.51 nM) and histamine-induced bronchoconstriction in guinea pigs via aerosol administration of doses ranging from 0.12 to 12 mM. Salmeterol binds to an exosite domain of β₂-adrenergic receptors, producing a slow onset of action and prolonged activation. Formulations containing salmeterol have been used in the treatment of asthma, including exercise-induced asthma, and chronic obstructive pulmonary disease.
Chemische Eigenschaften
White to Off-White Solid
Originator
Glaxo (United Kingdom)
Verwenden
Bronchodilator; Beta2-adrenoceptor agonist
Verwenden
Smooth wheezing anti-inflammatory
Verwenden
A β2-Adrenergic agonist. Structural analog of Albuterol (A514500).
Verwenden
A ?-Adrenergic agonist. Structural analog of albuterol
Application
Salmeterol xinafoate is a potent and selective β2-adrenoceptor agonist (EC50 = 5.3 nM) that displays bronchodilator actions. Unlike other β2- adrenoceptor agonists, Salmeterol binds to exo-site domain of β2-AR receptors, producing a slow onset of action and prolonged activation. Clinically used for the treatment of asthma and chronic obstructive pulmonary disease(COPD).
Definition
ChEBI: Salmeterol xinafoate is a naphthoic acid.
Trademarks
Serevent (GlaxoSmithKline).
Biochem/physiol Actions
β2-adrenoceptor agonist.
Lager
Desiccate at RT

Salmeterol xinafoate Upstream-Materialien And Downstream Produkte

Salmeterol xinafoate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

94749-08-3, Salmeterol xinafoate Verwandte Suche:

Send Inquriy